Program
empagliflozin
Also written as “BI 10773”, “Empagliflozin” and “BI10773”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Heart Failure · Diabetes Mellitus, Type 1 · Renal Insufficiency, Chronic · Diabetes Mellitus, Lipoatrophic, led by 15 companies.
Drug pageEmpagliflozin: every studyMany companies study it; this page follows only the 124 they lead. All 404 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 992 open or running | phase 4since Oct 27, 2015 | Nov 14, 2007 | Dec 11, 2026phase 1 · NCT07845630 |
| ADIUM | 40 open or running | no phasesince Mar 9, 2026 | Mar 9, 2026 | none ahead |
| Getz Pharmaits history only | 41 open or running | phase 4since Nov 27, 2020 | Nov 27, 2020 | Dec 31, 2026phase 4 · NCT05164263 |
| Gedeon Richter Plc.its history only | 30 open or running | phase 1since Dec 10, 2024 | Dec 10, 2024 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 21 open or running | phase 4since Jan 15, 2026 | Aug 1, 2016 | Aug 2027phase 4 · NCT07365358 |
| Dong Wha Pharmaceuticalits history only | 20 open or running | phase 1since Apr 10, 2023 | Apr 10, 2023 | none ahead |
| Kobe Universityits history only | 20 open or running | phase 3since Jul 10, 2019 | Jul 10, 2019 | none ahead |
| Celltrionits history only | 11 open or running | phase 3since Jun 30, 2025 | Jun 30, 2025 | Dec 2026phase 3 · NCT07093476 |
| Dong-A STits history only | 10 open or running | phase 1since Dec 5, 2018 | Dec 5, 2018 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Nov 16, 2021 | Nov 16, 2021 | none ahead |
| hyundai-pharmits history only | 11 open or running | phase 1since Jul 4, 2024 | Jul 4, 2024 | none ahead |
| Intarcia Therapeuticsits history only | 10 open or running | phase 3since Feb 9, 2017 | Feb 9, 2017 | none ahead |
| Nabiqasim Industries (Pvt)its history only | 11 open or running | phase 4since Feb 19, 2025 | Feb 19, 2025 | none ahead |
| pharma-nuevaits history only | 11 open or running | phase 1since Mar 6, 2024 | Mar 6, 2024 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 10 open or running | phase 4since Aug 14, 2017 | Aug 14, 2017 | none ahead |
Also a collaborator on its studies: Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of ADIUM only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 9, 2026First study: no phase study in BioequivalanceFirst studyNCT07479108 · 32 enrolled · Mexico
- Jun 3, 20263 no phase studies in Bioequivalence Study in Healthy SubjectsNCT07633054, NCT07633041, NCT07633028
TargetBeta
“An orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity”NCIt, by rule
“Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule
Other programs on SLC5A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| dapagliflozin | AstraZeneca | phase 4 | 133 |
| ertugliflozinrule | Merck | phase 4 | 22 |
| Enavogliflozinrule | Daewoong Pharmaceutical | phase 3 | 25 |
| vicadrostat | Boehringer Ingelheim | phase 3 | 16 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
Studies
All 4 ADIUM leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07633054Bioequivalence Study in Healthy Subjects · Mexico | – | Completed | Nov 24, 2025 | 42 |
| NCT07633041Bioequivalence Study in Healthy Subjects · Mexico | – | Completed | Apr 4, 2025 | 42 |
| NCT07633028Bioequivalence Study in Healthy Subjects · Mexico | – | Completed | Apr 8, 2025 | 42 |
| NCT07479108Bioequivalance · Mexico | – | Completed | Dec 11, 2024 | 32 |
How it is read
Names in the registry
- “BI 10773”, 71 entries
- “Empagliflozin”, 53 entries
- “BI10773”, 7 entries
- “Empagliflozin/Metformin”, 4 entries
- “Empagliflozin + Linagliptin”, 4 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 67 studies
- Heart Failure, 6 studies
- Diabetes Mellitus, Type 1, 5 studies
- Renal Insufficiency, Chronic, 4 studies
- Diabetes Mellitus, Lipoatrophic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.